Proactiveinvestors USA & Canada Neurotrope Proactiveinvestors USA & Canada Neurotrope RSS feed en Mon, 24 Jun 2019 06:01:17 -0400 Genera CMS (Proactiveinvestors) (Proactiveinvestors) <![CDATA[Media files - Neurotrope anticipates data from its drug to treat Alzheimer's summer 2019 ]]> Mon, 11 Feb 2019 21:53:00 -0500 <![CDATA[News - Neurotrope and Anavex are 'making progress' with Alzheimer's programs, says Maxim Group ]]> Analysts at Maxim Group viewed clinical trial data presented by Neurotrope Inc (NASDAQ:NTRP) and Anavex Life Sciences Corp (NASDAQ:AVXL) at the Alzheimer's Association International Conference as “an incremental positive” for the companies.

Maxim analysts reiterated their Buy ratings for both the biotechs based on what they heard at the conference.

New York-based biotech Neurotrope presented additional clinical results from its previously completed Phase 2 trial of Alzeheimer's drug Bryostatin-1 aimed at helping patients suffering from moderate to severe cases of the mind-robbing disease.

Key takeaways

“Cognition decline didn't just slow down like in other Alzheimer's disease trials, it actually improved. Patients improved after drug was stopped, suggesting synapses are being regenerated,” wrote Maxim Group analysts Caroline Palomeque and Jason McCarthy in a research note released Thursday.

READ: Biogen draws favorable attention following success of Phase 2 Alzheimer's disease study

Interestingly, Neurotrope’s lead product candidate bryostatin, is a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The experimental drug is targeting “moderate to severe” Alzheimer’s, while companies like Biogen Inc (NASDAQ:BIIB) are targeting earlier stages of the disease.  

Neurotrope is also developing bryostatin for other neurodegenerative or cognitive diseases and dysfunctions.

The analysts said a “confirmatory Phase 2 study” is underway to validate bryostatin’s results presented at the Alzheimer’s conference. The results are expected in mid-2019.

Data from Anavex 

New York-based Anavex Life Sciences, which engages in the development of drug candidates for the treatment of Alzheimer's, other central nervous system diseases, and cancers, also presented data at the conference.

“Two gene variants found in Alzheimer's disease patients translate to less likely to respond to 2-73. Exclusion of these patients from data analysis of Phase 2 trial showed improvement in cognition and function scores,” wrote the analysts. “Biomarkers being incorporated into P2b/3 trial which could "enrich" for Alzheimer's disease patients more likely to respond to 2-73.”

Palomeque and McCarthy viewed the biomarker approach potentially applicable to other central nervous system diseases like Rett and Parkinson's.

Biogen’s impact on the Alzheimer’s space

The analysts drew attention to Biogen’s promising results on an experimental Alzheimer’s drug BAN2401 and how it could impact other drug makers like Neurotrope and Anavex.

Massachusetts-based Biogen and Tokyo-based Eisai Co this week released data from a medical study that showed their drug, taken at high doses, removed a brain protein found in Alzheimer's patients and slowed memory and thinking problems of people in early stages of the disease. 

Patients who took the highest doses of the experimental drug twice a month via IV had the most significant reduction of beta amyloid, a protein that accumulates in the brains of Alzheimer's patients. 

Up until now drug companies have invested billions on failed drug trials that target amyloid, which is thought to cause the disease by accumulating in the brain and messing up communication between brain cells, killing them.

"A string of clinical trial failures prompted many to question whether drug companies were on the right track," noted USA Today.

“The Alzheimer’s Disease space has come into focus as of late, particularly following the BAN2401 data from Biogen which has had an impact on others in the space including Neurotrope Inc and Anavex Life Sciences,” wrote the analysts.

“Both companies are making progress with their respective programs and we look forward to data in 2019, which if positive represent significant catalysts for both companies,” they added.

Maxim has a US$16 price target on Neurotrope, and a US$7 price target on Anavex stock.

Shares in Neurotrope declined 2.3% to US$10.01 on Friday, while Anavex stock sank 4.07% to US$2.83.

Contact Uttara Choudhury at

Follow her on Twitter: @UttaraProactive

Fri, 27 Jul 2018 12:35:00 -0400
<![CDATA[News - Neurotrope welcomes industry veteran to board ]]> Neurotrope (OTCMKTS: NTRP), which is developing a disruptive therapy for the treatment of severe Alzheimer’s disease, has appointed an industry veteran to the board.

Dr Susanne Wilke will replace Larry Alstiel, who resigned to pursue a new, full-time professional opportunity.  

"We are very pleased to welcome Susanne to our board," said Charles S. Ramat, President and CEO of Neurotrope.

"She is an industry veteran with a tremendous scientific background including a dual Ph.D. in Chemistry and Biochemistry and extensive understanding of various therapeutic areas.

"Susanne’s proven experience in scientific operations, strategic planning and managing the growth of emerging companies will prove invaluable as we advance Bryostatin-1 through our Phase 2b proof-of-concept trial in moderately-severe to severe Alzheimer’s disease.”

Wilke is the Co-founder and CEO of CrossBridge International, an advisory specializing in integrating proprietary scientific developments with sophisticated marketing and financing plans for biotech companies.

Dr. Wilke also served as Director of the Life Sciences group at Wombat Capital Markets SAS, a financial advisory firm specializing in cross-border transactions between the U.S. and Europe.

Neurotrope has successfully completed a Phase 2a trial, in which all primary endpoints were met, and is currently dosing patients in a Phase 2b proof-of-concept trial.

Fri, 19 Feb 2016 09:20:00 -0500
<![CDATA[News - Thursday's followed - global share sell off and contrary Tesla ]]> The turmoil in global equities and the oil price slide  continues - with West Texas Intermediate -  now hovering around the US$27 mark - below what was called the last "pyschological" cut-off of US$30.

It is a topsy turvy world indeed currently, so no surprise perhaps then, that  luxury car maker Tesla (NASDAQ:TSLA) - and Elon Musk baby -  throws out another curved ball today.

Shares in the tech/ automobile firm added over 6% in New York and surged after hours after it posted quarterly earnings, which sent out a myriad of mixed fumes (although of course it didn't, cos it's electric vehicles).

On the one hand, the quarterly figures were disappointing, and less than analysts had hoped,  with an adjusted loss of 87 cents per share on US$1.75bln in sales.

But on the other there was positive news on production targets for this year and for those that follow the firm closely, exciting news that the new Model 3 vehicle will go on sale from March 31.

This is the first "moderately" priced electric car, which some  may be surprised to hear has a starting price of US$35,000.

Tesla also said it expects to ship 80,000 to 90,000 Model S and Model X cars in 2016, beating forecasts that the company would only ship about 76,000.

So what else was going on?

Junior biotech Neurotrope (OTCMKTS:NTRP) shares edged up 2.5% as it had some news on a potential treatment for devastating Alzheimer’s disease.

First patients have been dosed in its phase 2b clinical trial of lead candidate Bryostatin-1 for the advanced form of the disease.

The company expects to report three month interim data during the first quarter of 2017 with complete six month data set expected during the first half of 2017.


Tesla Motors (NASDAQ:TSLA) accelerates 6.5% to US$152.96 atfre the automaker gave a forecast for deliveries of its Model X that topped analyst estimates, and also said it expected to be profitable this year.

Expedia (NASDAQ:EXPE) jumps 8.2% to US$102.05 after giving an upbeat 2016 profit forecast.

Tripadvisor (NASDAQ:TRIP) soars 15.6% to US$62.85 after reporting adjusted quarterly profit and revenue above estimates. It benefited from higher ad sales and an increase in subscriptions.


Monster Worldwide (NYSE:MWW) cascades 34% to US$2.82 as it reported a decline in sales for its fourth quarter, which were worse than analysts had feared.

Twitter drops (NYSE:TWTR) 4.3% to US$14.33 after the key metric of monthly average users fell, and the company gave current quarter revenue guidance that falls below Street forecasts.

SolarCity (NASDAQ:SCTY) extends Wednesdays to fall a further 7.8% to US$17.18 after chief financial officer Brad Buss resigned, replaced by SolarCity President Tanguy Serra, in wake of poorly received 2015 earnings.



Thu, 11 Feb 2016 13:29:00 -0500
<![CDATA[News - Neurotrope candidate in bid to treat Alzheimer's ]]> Thu, 11 Feb 2016 09:08:00 -0500 <![CDATA[News - Neurotrope raising US$15.3mln to fund Alzheimer’s drug trial ]]> Neurotrope (OTCMKTS:NTRP) told investors it is raising US$15.3mln to fund the clinical development of its potential Alzheimer’s drugs.

It is part of a series of share issues - via conversion of preferred stock and/or warrants – that could see more than US$100mln of additional funding for the group.

Cash raised will support a Phase 2b clinical trial, which will study 150 patients with moderately severe to severe Alzheimer's disease.

The company has an exclusive license to develop and commercialize bryostatin, which is described as a ‘potent modulator’ of an enzyme call protein kinase C epsilon (PKCe).

PKCe deficit is seen as a potential cause of Alzheimer’s disease. Neurotrope highlights that in animal research the activation of PKCe has shown to improve learning and memory. It also highlighted that PKCe has been studied extensively by the Blanchette Rockefeller Neurosciences Institute (BRNI) as a possible treatment of cognitive disorders.

Initially, the company’s private placement will result in the raise of US$15.3mln with units sold to investors at 60 American cents each. Each unit will comprise one one-hundredth of a preference share (which can be converted later into common stock) and five separate share warrants.

If all warrants were exercised Neurotrope would raise US$136mln on top of the initial US$15.3mln funding.

Subscribers in the private placing will also be given the right to participate in any future equity financings over the next year.

Mon, 16 Nov 2015 09:34:00 -0500